Clay B. Siegall is quite confident of the future being very bright for ADCs and Seattle Genetics, Inc. This is because Seattle Genetics’ ADCETRIS┬« happens to be the first in a completely new class of ADCs. Hence the next step for Seattle Genetics in this field of ADCs will be a decision from the FDA with regard to the supplemental Biologics License Application. This will be for ADCETRIS in the AETHERA setting. It will be for the post-transplant consolidation treatment that can be done for Hodgkin lymphoma patients who are at high risk of relapse or even progression. There are nearly 50 percent of HL patients who may be at this risk of undergoing an autologous stem cell transplant and risk a relapse. There have been very few therapeutic advances which can help to improve patient outcomes.

Clay B. Siegall also mentioned about three other phase 3 clinical trials which are ongoing. These are namely ALCANZA, ECHELON-1 as well as ECHELON-2. Here ALCANZA is basically a randomized trial of ADCETRIS. Complete enrollment to ALCANZA is expected this year. The ECHELON trials help in the goal of redefining the way in which frontline HL as well as mature T-cell lymphoma patients will get treated as this will be done by adding ADCETRIS into the standard regimen but by dropping its most toxic agents. The complete enrollment to ECHELON-1 is expected to complete later this year. The data readouts will get completed for the trial in the timeframe of 2017 to 2018.

After ADCETRIS, next will be seven clinical-stage programs. The lead ADC programs will include SGN-CD33A in acute myeloid leukemia along with SGN-CD19A in non-Hodgkin lymphoma. All these have already generated encouraging data as per Clay B. Siegall.

Next, there will be collaborations with a dozen leading biotechnology as well as pharmaceutical companies. Their technology is able to empower over 20 of the ADCs that are in clinical development through proprietary as well as collaborator programs.

There have to be critical considerations with regard to ADC development that would include an internalizing antibody which would be targeted to a highly specific tumor antigen.